قالب وردپرس درنا توس
Home / Business / One injection of Johnson & Johnson has been cleared, providing the United States with the third COVID-19 vaccine

One injection of Johnson & Johnson has been cleared, providing the United States with the third COVID-19 vaccine



Washington (Associated Press)-The United States is getting a third vaccine against COVID-19 because the US Food and Drug Administration (FDA) approved a Johnson & Johnson injection method on Saturday that uses only one dose. Not two doses.

Health experts are eager to adopt a once-and-for-all option to help speed up vaccination as they compete with a virus that has killed more than 510,000 people in the United States and is mutating in an increasingly worrying way .

The FDA says Johnson & Johnson’s vaccines provide strong protection for the most important diseases: serious illness, hospitalization, and death. In a large-scale study spanning three continents, one dose was 85% protective against the most serious COVID-1

9 disease-even in a country like South Africa where the most concerned variant spreads, the protective effect is still strong .

Dr. Francis Collins, director of the National Institutes of Health, told the Associated Press: “This is really good news.” “The most important thing we can do now is to shoot as much as possible.”

Johnson & Johnson initially provided several million doses, and may start shipping to states as early as Monday. Johnson & Johnson has stated that by the end of March, it expects to provide 20 million doses to the United States and 100 million doses by the summer.

Johnson & Johnson is also seeking authorization for emergency use of its vaccines in Europe and the World Health Organization (WHO). The company’s goal is to produce approximately 1 billion doses globally by the end of this year. On Thursday, the island nation of Bahrain became the first country to clear its use.

President Joe Biden said in a statement: “This is exciting news for all Americans, and it is an encouraging development in our efforts to end this crisis.” He added: “But I want to be clear: this fight is not over yet.” He encouraged people to insist on wearing masks and other public health measures.

On Sunday, the US Advisory Committee will meet to recommend how to prioritize the use of single-dose vaccines. The big challenge the public wants to know is: Which is better?

Dr. Arnold Monto of the University of Michigan said: “In this environment, everything you can get-get.” He chaired the FDA advisory group, which unanimously voted on Friday that the benefits of the vaccine outweigh the risks.

Data on how effective all the vaccines used around the world are mixed together, prompting people in some countries to reject reports of one vaccine waiting for another.

In the United States, the protection rate of two doses of Pfizer and Moderna against symptomatic COVID-19 is 95%. The effective rate of one dose of Johnson & Johnson’s anti-severe COVID-19 dropped to 66% at the time of transfer of moderate cases. But because of when and where each company conducts the research, the Moderna research has been completed with Pfizer and before the research on variants began to spread.

Collins of the National Institutes of Health said there is no reason to prefer one vaccine over another.

“I think the person who is most interested is, will this prevent me from getting really sick?” Collins said. “Will this save me from dying from this terrible disease? The good news is that all of them say yes.”

In addition, Johnson & Johnson is testing two doses of the vaccine in another large study. Collins said that if the second dose is ultimately deemed better, then people who took one earlier will get another dose.

The FDA cautioned that it is too early to say whether people with mild or asymptomatic infections despite being vaccinated can still transmit the virus.

In addition to convenient shooting, there are obvious advantages. Local health officials are seeking to use Johnson & Johnson’s option in mobile vaccination clinics and homeless shelters. Even if sailors spend months on fishing boats, it is difficult to be certain in the community that someone will be in three to four places. Vaccination again within a week.

Compared with Pfizer and Moderna, which must be frozen, Johnson & Johnson vaccine is easier to handle and can be stored in the refrigerator for three months.

“We are working hard to secure more supplies. This is currently a limiting factor for us.” Dr. Matt Anderson of UW Health in Madison, Wisconsin, said that staff there are preparing electronic health records, personnel and vaccine storage, with a view to Provide Johnson & Johnson vaccine soon.

The FDA said the study found no serious side effects. Like other COVID-19 vaccines, the main side effects of Johnson & Johnson injection are pain at the injection site and flu-like fever, fatigue and headache.

The FDA’s fact sheet for vaccinators said that people have “very little chance” of having a severe allergic reaction to the vaccine, which is a rare risk for Pfizer and Moderna vaccines. This reaction is treatable, and the vaccine recipient should be monitored briefly after the injection.

Currently, the vaccine has been approved for emergency use in adults 18 years and older. But like other manufacturers, Johnson & Johnson will study how it works in adolescents before turning to younger children later this year, and also plans to conduct research on pregnant women.

All COVID-19 vaccines train the human body to recognize new coronaviruses, usually by discovering tricky proteins covering them. But their production methods are quite different.

Johnson & Johnson’s shooting uses a cold virus such as a Trojan horse to bring the spike gene into the body. In this case, the cell can copy the protein harmlessly and activate the immune system when the real virus appears. This is the same technology that the company uses to produce the Ebola vaccine, similar to the COVID-19 vaccine produced by AstraZeneca and CanSino Biologics in China.

Pfizer and Moderna vaccines use another technology, a genetic code called messenger RNA that stimulates cells to produce copies of those harmless spikes.

The AstraZeneca vaccine, already in use in the United Kingdom and many other countries, is completing a large study required for FDA approval in the United States. Novavax, which is also in development, uses another technology, which is replicated from laboratory-grown spike proteins, and has reported a preliminary finding from a British study that shows its powerful protective effect.

Other countries are using “inactivated vaccines” made from killed coronaviruses by Chinese companies Sinovac and Sinopharm.

___

Associated Press reporters Ricardo Alonso Zardiva and Marion Renault contributed to this report.

___

The Associated Press Department of Health and Science is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.


Source link